Galena planning follow-on

Galena Biopharma Inc. (NASDAQ:GALE) proposed a follow-on late Thursday underwritten by Oppenheimer. Galena's NeuVax is in the Phase III PRESENT trial to prevent recurrence of early stage, node-positive breast cancer with low to intermediate HER2 expression. NeuVax is a vaccine comprising an immunogenic peptide derived from epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2; neu) and sargramostim. Galena also has U.S. commercialization rights from Orexo AB (SSE:ORX) to Abstral fentanyl, a sublingual mucoadhesive formulation of the mu opioid receptor agonist approved in the U.S. to treat breakthrough cancer pain. ...